Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection
Open Access
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 10 (4) , 337-339
- https://doi.org/10.1111/j.1198-743x.2004.00827.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Definitions of Cytomegalovirus Infection and Disease in Transplant RecipientsClinical Infectious Diseases, 2002
- Pulmonary Cytomegalovirus Infection in Immunocompromised PatientsChest, 2001
- CYTOMEGALOVIRUS INFECTION AND GRAFT REJECTION IN RENAL TRANSPLANTATIONTransplantation, 2001
- LONG-TERM ORAL GANCICLOVIR PROPHYLAXIS FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN CYTOMEGALOVIRUS HIGH-RISK RENAL TRANSPLANT RECIPIENTSTransplantation, 2000
- Cytomegalovirus (CMV)–Specific T Cell Immunity after Renal Transplantation Mediates Protection from CMV Disease by Limiting the Systemic Virus LoadThe Journal of Infectious Diseases, 1999
- Preemptive Ganciclovir Therapy in Cytomegalovirus-Seropositive Renal Transplants RecipientsArchives of Surgery, 1995
- Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant RecipientsAnnals of Internal Medicine, 1995
- Infectious disease complications of renal transplantationKidney International, 1993
- Symptomatic Cytomegalovirus Infection in Renal Transplant Recipients Given Either Minnesota Antilymphoblast Globulin (MALG) or OKT3 for Rejection ProphylaxisAmerican Journal of Kidney Diseases, 1993
- SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2Transplantation, 1992